Product Code: RP-ID-10086129 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086129
Market Overview:
Global Haemophilia Market - Analysis By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023) -- By Region (North America, Europe, APAC, ROW), By Country (U.S, Canada, Germany, UK, Japan, China, India, Brazil) 2022-2030
"In 2021, the global hemophilia market is estimated to be valued at ~USD 15 billion and is expected to grow at a compound annual growth rate of ~6% during the forecast period 2022-2030. The increase in research and development programs, especially in the identification of therapeutic drugs, is one of the main factors that are expected to have a positive impact on market growth. Limited treatment options and the increasing burden of regulatory agencies on their treatments have led to increased research and development efforts.
In addition, the government plans to strengthen publicity activities and support initiatives to start screening newborns, which is expected to increase the demand for diagnostic tools related to hemophilia. According to data released by the WFH (World Federation of Hemophilia), there are more records of hemophilia among men, with about 1 in 5,000 newborns having type A. This is a rare inherited bleeding disorder that is expected to affect approximately 440,000 people worldwide in 2018. Promote overall market growth. Institutions such as the American Hemophilia Association usually introduce different co-payment plans to provide continuous treatment for patients, which is also expected to balance patient costs and help them obtain new products. For example, CSL Behring launched the "MyAccess Cost Sharing Program" for American patients, providing treatment costs of up to $12,000.
TYPE INFORMATION:
According to the type, the market is divided into type A, type B, type C and other hemophilia. The classification is based on the coagulation factor deficiency of the specific patient. It is generally observed that type A is the most common type, and is recorded four times as much as type B hemophilia. According to statistics released by WebMD LLC in 2019, the prevalence of type A varies from country to country, ranging from 5.4 to 14.5 cases per 100,000 men.
In addition, about 50-60% of patients with severe hemophilia A have severe bleeding. In addition, most of the available products are used to treat hemophilia A. However, due to the presence of strong products in the product portfolio, Type B is expected to be the fastest growing segment during the forecast period. In addition, type B accounts for approximately 20% of global hemophilia cases, and 50% of them have factor IX levels greater than 1%.
TREATMENT INFORMATION:
According to treatment, the hemophilia market is divided into prevention and on-demand treatment. On Demand has the largest market share in 2019, and prevention is expected to be the fastest growing segment during the forecast period. Patients, this leads to its growth rate. The duration of this treatment depends on the severity of the patient. In addition, preventive treatment is expected to reduce productivity losses and improve quality of life.
TREATMENT INFORMATION:
The main therapies on the market include Immune Tolerance Induction Therapy (ITI), Alternative Therapy and Gene Therapy. It is expected that alternative therapies in 2022 will be the largest market segment, and gene therapy is expected to be the fastest growing market segment during the forecast period. Replacement therapy is considered to be the standard therapy used in treatment, helping to replace the missing clotting factors in the patient. The field of gene therapy is one of the emerging fields, especially in the recognition of defective DNA bases and functional base repair. AMT-060 is a potential therapy developed by UniQure to treat type B and is undergoing clinical trials.
The therapy restores the production of factor IX in the patients body by passing a working copy of the factor IX gene to the liver cells of type B patients. In addition, initiatives taken by various companies to develop gene therapies for hemophilia include Spark Therapeutics Inc.; Unique; BioMarin is expected to drive the growth of this segment.
REGIONAL INSIGHT:
In 2020, North America dominated the market, contributing more than 45% of revenue share. The rising prevalence and the increasing trend of preventive treatment are expected to become the initial driving force of regional growth. In the United States, people are diagnosed with this disease at an early age. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period. In countries such as Japan, India, Indonesia, and Malaysia, the early diagnosis of the disease and the increase in per capita use of therapies for factor VIII and IX deficiencies are driving factors affecting life. ); CSL Behring; Pfizer; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Genzyme; Chugai Pharmaceutical Co., Ltd.; Novo Nordisk A/S .; and Octapharma AG.
MAJOR PLAYERS:
Focus on new product development, mergers and acquisitions, and regional expansion to achieve greater market share. For example, Spark Therapeutics Inc. is involved in the development of SPK-8011 for the treatment of Type A, and clinical trials are currently underway. In addition, in 2018, Sanofi acquired Bioverativ, an American hemophilia expert, for US$11.6 billion to strengthen its market share in the rare disease product portfolio.
MARKET SEGMENTS COVERED BY THE REPORT:
The report forecasts global, regional and national revenue growth, and analyzes the latest industry trends in each sub-segment from 2022-2030. For the purpose of this research, Kenneth Research will report on the global hemophilia market based on products, treatments, therapies, and regions: Type Outlook (Revenue, USD million, 2022-2030) Hemophilia B Hemophilia Treatment Outlook (Revenue , USD million, 2022-2030) Outlook for on-demand preventive treatment (income, USD million, 2022-2030) Alternative Therapy ITI Therapy Gene Therapy."
Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst BioSciences, Dimension Therapeutics, Shire, CSL Behring, Alnylam Pharmaceuticals .
Related Reports
Proof of Quality & Reliability
